Mikhailidis DP - Search Results

1

The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis.

Karagiannis A, Tziomalos K, Anagnostis P, Gossios TD, Florentin M, Athyros VG, Mikhailidis DP. Karagiannis A, et al. Among authors: mikhailidis dp. Curr Vasc Pharmacol. 2010 Nov;8(6):792-803. doi: 10.2174/157016110793563906. Curr Vasc Pharmacol. 2010. PMID: 20626344 Review.

2

The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?

Karagiannis A, Mikhailidis DP, Athyros VG, Kakafika AI, Tziomalos K, Liberopoulos EN, Florentin M, Elisaf M. Karagiannis A, et al. Among authors: mikhailidis dp. Expert Opin Ther Targets. 2007 Feb;11(2):191-205. doi: 10.1517/14728222.11.2.191. Expert Opin Ther Targets. 2007. PMID: 17227234 Review.

3

Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?

Karagiannis A, Mikhailidis DP, Kakafika AI, Tziomalos K, Athyros VG. Karagiannis A, et al. Among authors: mikhailidis dp. Curr Pharm Des. 2007;13(2):229-39. doi: 10.2174/138161207779313713. Curr Pharm Des. 2007. PMID: 17269930 Review.

4

Atherogenesis in renal patients: a model of vascular disease?

Efstratiadis G, Tziomalos K, Mikhailidis DP, Athyros VG, Hatzitolios A. Efstratiadis G, et al. Among authors: mikhailidis dp. Curr Vasc Pharmacol. 2008 Apr;6(2):93-107. doi: 10.2174/157016108783955374. Curr Vasc Pharmacol. 2008. PMID: 18393910 Review.

5

Should adipokines be considered in the choice of the treatment of obesity-related health problems?

Athyros VG, Tziomalos K, Karagiannis A, Anagnostis P, Mikhailidis DP. Athyros VG, et al. Among authors: mikhailidis dp. Curr Drug Targets. 2010 Jan;11(1):122-35. doi: 10.2174/138945010790030992. Curr Drug Targets. 2010. PMID: 20017725 Review.

6

Endocrine hypertension: diagnosis and management of a complex clinical entity.

Anagnostis P, Karagiannis A, Tziomalos K, Athyros VG, Kita M, Mikhailidis DP. Anagnostis P, et al. Among authors: mikhailidis dp. Curr Vasc Pharmacol. 2010 Sep;8(5):646-60. doi: 10.2174/157016110792006996. Curr Vasc Pharmacol. 2010. PMID: 20180774 Review.

7

Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?

Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Athyros VG, et al. Among authors: mikhailidis dp. Curr Vasc Pharmacol. 2012 May;10(3):374-7. doi: 10.2174/157016112799959422. Curr Vasc Pharmacol. 2012. PMID: 22272896

8

Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics.

Koumaras C, Tzimou M, Stavrinou E, Griva T, Gossios TD, Katsiki N, Athyros VG, Mikhailidis DP, Karagiannis A. Koumaras C, et al. Among authors: mikhailidis dp. Am J Cardiovasc Drugs. 2012 Jun 1;12(3):143-56. doi: 10.2165/11599040-000000000-00000. Am J Cardiovasc Drugs. 2012. PMID: 22540323 Review.

9

Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview.

Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Katsiki N, et al. Among authors: mikhailidis dp. Curr Vasc Pharmacol. 2014;12(4):627-41. doi: 10.2174/15701611113119990131. Curr Vasc Pharmacol. 2014. PMID: 23627982 Review.

10

Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?

Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A. Katsiki N, et al. Among authors: mikhailidis dp. Curr Vasc Pharmacol. 2018;16(3):219-227. doi: 10.2174/1570161115666170621075619. Curr Vasc Pharmacol. 2018. PMID: 28669328 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,418 results

Search Page

Filters